LACY ENGELSTAD: Open Payments
NPI 1427712181 · COEUR D ALENE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$922 in 51 payments from 13 companies in 2025. Trend: 2023 $59 · 2024 $767 · 2025 $922
Food & beverage: $822Education: $100
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 15 | $334 |
| Janssen Biotech, Inc. | 7 | $159 |
| UCB, Inc. | 15 | $147 |
| AstraZeneca Pharmaceuticals LP | 5 | $96 |
| ABBVIE INC. | 1 | $33 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Lilly USA, LLC | 1 | $24 |
| SOBI, INC | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
Products named: TREMFYA, Bimzelx, KRYSTEXXA, SAPHNELO, ENBREL, RINVOQ, ORENCIA, TALTZ.
Industry payments across ID — which companies pay providers there.
